
Unilever under Pressure after GSK Consumer Bid Flop
Unilever’s CEO Alan Jope has had to bury his hopes of buying GlaxoSmithKline’s consumer drugs portfolio. After shareholders questioned the move, and analysts said that due to the relatively low price its third offer, worth £50 billion, was “as good as dead, the London-based consumer giant pulled the plug. Now it looks as if the CEO may face more trouble, as an activist investor has stepped into the fray.